Bifogade filer
Kurs
-2,16%
Prenumeration
Kalender
Tid* | ||
2025-05-08 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-05-05 | N/A | Årsstämma |
2025-02-21 | 08:00 | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-05-03 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2024-05-02 | - | Årsstämma |
2024-02-26 | - | Bokslutskommuniké 2023 |
2024-02-22 | - | Extra Bolagsstämma 2024 |
2023-11-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-10-28 | - | Kvartalsrapport 2022-Q3 |
2022-07-22 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-10-29 | - | Kvartalsrapport 2021-Q3 |
2021-08-13 | - | Kvartalsrapport 2021-Q2 |
2021-05-07 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2021-05-06 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-09-22 | - | Extra Bolagsstämma 2020 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-06-22 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2020-06-18 | - | Årsstämma |
2020-05-14 | - | Årsstämma |
2020-05-13 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-06-18 | - | Extra Bolagsstämma 2019 |
2019-05-17 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2019-05-16 | - | Årsstämma |
2019-05-14 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2018-05-14 | - | Kvartalsrapport 2018-Q1 |
2018-04-03 | - | Extra Bolagsstämma 2018 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-13 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-19 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2017-05-18 | - | Årsstämma |
2017-05-18 | - | Kvartalsrapport 2017-Q1 |
2017-03-07 | - | Kapitalmarknadsdag 2017 |
2017-02-27 | - | Bokslutskommuniké 2016 |
2016-11-21 | - | Kvartalsrapport 2016-Q3 |
2016-08-22 | - | Kvartalsrapport 2016-Q2 |
2016-05-27 | - | Kvartalsrapport 2016-Q1 |
2016-05-27 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
2016-05-26 | - | Årsstämma |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a rights issue and a directed issue of in total 1,499,673,033 shares. The share issues has resulted in a change of the registered share capital and shares and votes in Xbrane.
As of 31 March 2024, the total number of shares and votes in the Company amounts to 1,529,483,397. The Company's registered share capital amounts to approximately SEK 342,888,859.
Contacts
Martin Åmark, CEO
E: martin.amark@xbrane.com
Anette Lindqvist, CFO/IR
E: anette.lindqvist@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-04-01 08:30 CEST.